Concord Biotech Limited — Results, 29-05-2025: Integrated Filing- Financial

Concord Biotech has announced a board meeting on May 29, 2025, approving the financial results for the quarter and half-year.

1) Revenue Performance: Consolidated revenue rose to Rs. 1,200.09 Cr, up ~18% YoY from Rs. 1,016.94 Cr. Growth was driven primarily by its pharmaceutical manufacturing and trading segment.

2) Profitability and EPS: Net profit increased ~21% YoY to Rs. 371.64 Cr, with EPS improving to Rs. 35.52 from Rs. 29.45. Margins expanded due to volume growth and effective cost control.

3) Operational Costs: Expenses climbed to Rs. 748.66 Cr, largely from higher raw material costs (Rs. 264.31 Cr vs. Rs. 184.54 Cr) and employee benefits (Rs. 138.93 Cr vs. Rs. 123.05 Cr), reflecting scale-up and talent investment. Power and fuel costs remained stable, supporting operational efficiency amid growth.

4) Key Metrics: EBITDA and profitability trends are positive. Other income increased to Rs. 44.45 Cr, boosting net earnings. Joint venture losses were minimal.

5) Balance Sheet / Cash Flow Health: Equity expanded substantially to Rs. 1,81,271.75 Cr, supported by debt reduction through repayments. Operating cash flow stayed strong at Rs. 244.52 Cr, funding capex of Rs. 111.17 Cr. Though cash balances dipped to Rs. 0.90 Cr due to investments and debt payoff, overall liquidity remains solid.

6) Management Outlook: A proposed dividend of Rs. 10.70 per share signals confidence in cash flows and rewards shareholders. Leadership updates aim to strengthen governance.

Final Takeaway: Concord Biotech exhibits solid topline and bottom-line growth with disciplined cost management and healthy cash generation. The company’s robust balance sheet and strategic focus position it well for sustainable expansion, making it attractive to retail investors seeking steady pharma sector exposure.